Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on July 8, 2005
Japanese Journal of Clinical Oncology 2005 35(8):478-482; doi:10.1093/jjco/hyi122
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/8/478    most recent
hyi122v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Onoda, S.
Right arrow Articles by Masuda, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Onoda, S.
Right arrow Articles by Masuda, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2005 Foundation for Promotion of Cancer Research

Case Report

Drug Interaction Between Gefitinib and Warfarin

Sayaka Onoda, Hisashi Mitsufuji, Nobuo Yanase, Shinichiro Ryuge, Emi Kato, Mayumi Wada, Kaori Ishii, Shintaro Hagiri, Michiko Yamamoto, Masanori Yokoba, Tomoko Yanaihara, Masaru Kuboto, Nobukazu Takada, Masato Katagiri, Tadashi Abe, Naohiko Tanaka, Hirosuke Kobayashi and Noriyuki Masuda

Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

For reprints and all correspondence: Hisashi Mitsufuji, Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-0022, Japan. E-mail: kokyuki{at}kitasato-u.ac.jp

Received January 6, 2005; accepted March 8, 2005

Gefitinib is a synthetic, oral anilinoquinazoline specifically designed to inhibit the epidermal growth factor receptor tyrosine kinase, and is the first targeted drug to demonstrate reproducible activity in non-small cell lung cancer patients who do not respond to platinum-based chemotherapy. In this report, we present two cases of an interaction between gefitinib and warfarin which has not been reported previously. Because of the potentially serious consequences of this interaction, close monitoring of the International Normalized Ratio and warfarin dosage adjustment are recommended for patients receiving warfarin together with gefitinib.

Key Words: gefitinib • warfarin • drug interaction • International Normalized Ratio • non-small cell lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
C.-M. Wong, Y. Ko, and A. Chan
Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: Profiling and Comparison of Two Drug Compendia
Ann. Pharmacother., December 1, 2008; 42(12): 1737 - 1748.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.